Compare ATLX & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATLX | MXCT |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 136.0M |
| IPO Year | 2012 | 2021 |
| Metric | ATLX | MXCT |
|---|---|---|
| Price | $3.20 | $1.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $5.50 |
| AVG Volume (30 Days) | 415.1K | ★ 1.7M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $92,491.00 | ★ $33,026,000.00 |
| Revenue This Year | $64,564.67 | N/A |
| Revenue Next Year | $785.59 | $18.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.07 | $0.64 |
| 52 Week High | $8.25 | $2.37 |
| Indicator | ATLX | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 33.56 | 74.15 |
| Support Level | N/A | $0.77 |
| Resistance Level | $3.92 | $1.71 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 15.88 | 78.33 |
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.